Abstract:BackgroundColorectal cancer is the third most common cancer. Involvement of prostaglandin (PG) system in the pathogenesis of colorectal cancer has been suggested from clinical studies demonstrating therapeutic effect of NSAIDs including aspirin or selective COX-2 inhibitors. However, mechanisms on how PG regulates inflammatory responses leading to colorectal cancer development remain obscure. Further, careful attention is needed to use these drugs for a long time because of adverse effects due to non-specific inhibition of physiological PG production in addition to pathological one, making the development of alternatives to aspirin important. Recent studies using mouse model of colitis-associated colon cancer, azoxymethane (AOM)-dextran sodium sulfate (DSS) model, have revealed some of the mechanisms on how PG regulates inflammation in lesions and proposed PG receptor as a therapeutic target.Main body of abstractAmong each PG receptor subtype examined, prostaglandin E receptor 2 (EP2) signaling specifically contributes to colorectal cancer formation and inflammation in lesions of AOM-DSS model. EP2 is expressed in neutrophils, infiltrated major inflammatory cells, and tumor-associated fibroblasts (TAFs) in the tumor stroma of this mouse model and also in clinical specimen from ulcerative colitis-associated colorectal cancer. Bone marrow transfer experiments between wild-type and EP2-deficient mice have confirmed the involvement of EP2 signaling in these two types of cells in the pathogenesis of the disease. EP2 signaling in both types of cells regulates the transition to and maintenance of inflammation in multiple steps to shape the tumor microenvironment which contributes to trigger and promote colorectal cancer. In this process, PGE2-EP2 signaling synergizes with TNF-α to amplify TNF-α-induced inflammatory responses, forms a positive feedback loop involving COX-2-PGE2-EP2 signaling to exacerbate PG-mediated inflammation once triggered, and alternates active cell populations participating in inflammation through forming self-amplification loop among neutrophils. Thus, EP2 signaling functions as a node of inflammatory responses in the tumor microenvironment. Based on such a notion, EP2 can become a strong candidate for therapeutic target of colorectal cancer treatment. Indeed, in AOM-DSS model, a selective EP2 antagonist, PF-04418948, potently suppresses colorectal tumor formation.Short conclusionPGE2-EP2 signaling functions as a node of chronic inflammation which shapes the tumor microenvironment and thus is a strong candidate of target for the chemoprevention of colorectal cancer.

CXCL1 Induced by Prostaglandin E2 Promotes Angiogenesis in Colorectal Cancer.

Intracrine Vegf Signalling Mediates Colorectal Cancer Cell Migration and Invasion

Abstract 365: Autocrine Vascular Endothelial Growth Factor Signaling Mediates Survival and Chemoresistance of Human Colorectal Cancer Cells

Cyclooxygenase-2 Induces Angiogenesis in Pancreatic Cancer Mediated by Prostaglandin E-2

Progastrin a new pro-angiogenic factor in colorectal cancer

ANGPTL1 Attenuates Colorectal Cancer Metastasis by Up-Regulating Microrna-138

Prostaglandin E2-EP2 signaling as a node of chronic inflammation in the colon tumor microenvironment

CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer

Upregulation of CPE promotes cell proliferation and tumorigenicity in colorectal cancer

Prostaglandin E-2 Promotes Colorectal Adenoma Growth Via Transactivation Of The Nuclear Peroxisome Proliferator-Activated Receptor Delta

Prostaglandin E Receptor 4 (EP4) Promotes Colonic Tumorigenesis

Abstract A001: Colorectal Cancer Cell-Derived Exosomes Containing Mir-183-5p Regulate Angiogenesis Via FOXO1

Chemokine (C-X-C Motif) Ligand 1 is Associated with Tumor Progression and Poor Prognosis in Patients with Colorectal Cancer

Mechanisms involved in biological behavior changes associated with Angptl4 expression in colon cancer cell lines.

Prostaglandin E-2 Enhances Intestinal Adenoma Growth Via Activation of the Ras-Mitogen-Activated Protein Kinase Cascade

Tumor-Derived GM-CSF Promotes Inflammatory Colon Carcinogenesis Via Stimulating Epithelial Release of VEGF

Chronic Inflammation and Colorectal Cancer: the Role of Vascular Endothelial Growth Factor

MicroRNA-181a promotes angiogenesis in colorectal cancer by targeting SRCIN1 to promote the SRC/VEGF signaling pathway

PDPN/CCL2/STAT3 feedback loop alter CAF heterogeneity to promote angiogenesis in colorectal cancer

Platelet-derived growth factor-D promotes colorectal cancer cell migration, invasion and proliferation by regulating Notch1 and matrix metalloproteinase-9

Il-17 is Associated with Poor Prognosis and Promotes Angiogenesis Via Stimulating Vegf Production of Cancer Cells in Colorectal Carcinoma